InnoCan Pharma Corporation (INNO.CN)
InnoCan Pharma Corporation operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Calgary, AB, CA. The stock last traded at $2.30, up 4.55% on the session, giving a market capitalisation of $10.3M. Its beta of -0.22 implies it has historically moved less than the broad market.
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes. InnoCan's product line features a range of CBD-infused topical items, including eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Beyond R&D, the corporation is also involved in the marketing and distribution of its proprietary CBD-enhanced pharmaceutical and cosmetic offerings. Established in 2018, InnoCan Pharma Corporation maintains its principal office in Calgary, Canada.
InnoCan Pharma Corporation is most often compared with the following Healthcare names: